Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Daily Top 10 COVID-19 papers

DEU | ENG | ESP | FRA | ITA | POR | TUR | VNM


  Arrhythmias

  Free Subscription


Articles published in J Thromb Thrombolysis

Retrieve available abstracts of 71 articles:
HTML format



Single Articles


    May 2020
  1. WANG CL, Wu VC, Huang YT, Chen YL, et al
    Incidence and consequences of resuming oral anticoagulant therapy following hematuria and risks of ischemic stroke and major bleeding in patients with atrial fibrillation.
    J Thromb Thrombolysis. 2020 May 14. pii: 10.1007/s11239-020-02135.
    PubMed     Abstract available


  2. DUARTE RCF, Rios DRA, Figueiredo EL, Caiaffa JRS, et al
    Thrombin Generation and other hemostatic parameters in patients with atrial fibrillation in use of warfarin or rivaroxaban.
    J Thromb Thrombolysis. 2020 May 6. pii: 10.1007/s11239-020-02126.
    PubMed     Abstract available


    April 2020
  3. ZHANG L, Yan X, Fox KAA, Willmann S, et al
    Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in patients with non-valvular atrial fibrillation.
    J Thromb Thrombolysis. 2020 Apr 23. pii: 10.1007/s11239-020-02077.
    PubMed     Abstract available


  4. LIU W, Xiong N, Xie K, Wu B, et al
    A stricter control of low-density lipoprotein is necessary for thrombosis reduction in "lower thrombosis risk" patients with atrial fibrillation: a multicenter retrospective cohort study.
    J Thromb Thrombolysis. 2020 Apr 13. pii: 10.1007/s11239-020-02110.
    PubMed     Abstract available


  5. TOSELLI M, Bosi D, Benatti G, Solinas E, et al
    Left atrial appendage closure: a balanced management of the thromboembolic risk in patients with hemophilia and atrial fibrillation.
    J Thromb Thrombolysis. 2020 Apr 8. pii: 10.1007/s11239-020-02097.
    PubMed     Abstract available


    March 2020
  6. PETERSON BE, Bhatt DL
    Looking into the next decade of antithrombotic therapy for patients with atrial fibrillation and percutaneous coronary intervention.
    J Thromb Thrombolysis. 2020 Mar 12. pii: 10.1007/s11239-020-02081.
    PubMed     Abstract available


  7. UENO EI, Fujibayashi K, Sawaguchi J, Yasuda Y, et al
    Monitoring the roles of prothrombin activation fragment 1 and 2 (F1 + 2) in patients with atrial fibrillation receiving rivaroxaban and apixaban.
    J Thromb Thrombolysis. 2020 Mar 12. pii: 10.1007/s11239-020-02079.
    PubMed     Abstract available


    February 2020
  8. NOMURA E, Takemaru M, Himeno T, Kono R, et al
    Clinical features and efficacy of reperfusion therapy in minor ischemic stroke patients with atrial fibrillation.
    J Thromb Thrombolysis. 2020 Feb 11. pii: 10.1007/s11239-020-02057.
    PubMed     Abstract available


    January 2020
  9. KHEIRI B, Simpson TF, Stecker EC, Osman M, et al
    Antithrombotic therapy for atrial fibrillation with stable coronary artery disease: a meta-analysis of randomized controlled trials.
    J Thromb Thrombolysis. 2020 Jan 24. pii: 10.1007/s11239-020-02041.
    PubMed    


  10. JONES MJ, Eudaley ST, Moye RA, Hodge TA, et al
    Safety outcomes of apixaban in patients with nonvalvular atrial fibrillation and severe renal impairment.
    J Thromb Thrombolysis. 2020 Jan 4. pii: 10.1007/s11239-019-02028.
    PubMed     Abstract available


  11. MAMELI A, Schirru P, Porru M, Marongiu F, et al
    Underuse of anticoagulant therapy in hospitalized older patients: comment on the article of Wojszel et al.
    J Thromb Thrombolysis. 2020;49:136-137.
    PubMed    


    December 2019
  12. TAN BY, Leow AS, Teoh HL, Gopinathan A, et al
    High incidence of under-treated atrial fibrillation: perspectives from an Asian Stroke Endovascular Thrombectomy Registry.
    J Thromb Thrombolysis. 2019 Dec 13. pii: 10.1007/s11239-019-02019.
    PubMed    


  13. WERNLY B, Bhatt DL, Polzin A, Jung C, et al
    Antithrombotic therapy for chronic coronary syndrome and atrial fibrillation: less might be more.
    J Thromb Thrombolysis. 2019 Dec 3. pii: 10.1007/s11239-019-02007.
    PubMed     Abstract available


  14. ZHOU Y, He W, Zhou Y, Zhu W, et al
    Non-vitamin K antagonist oral anticoagulants in patients with hypertrophic cardiomyopathy and atrial fibrillation: a systematic review and meta-analysis.
    J Thromb Thrombolysis. 2019 Dec 2. pii: 10.1007/s11239-019-02008.
    PubMed     Abstract available


    November 2019
  15. DA COSTA FA, Mala-Ladova K, Lee V, Tous S, et al
    Awareness campaigns of atrial fibrillation as an opportunity for early detection by pharmacists: an international cross-sectional study.
    J Thromb Thrombolysis. 2019 Nov 28. pii: 10.1007/s11239-019-02000.
    PubMed     Abstract available


  16. PRENTICE A, Ruiz I, Weeda ER
    Medication adherence to rivaroxaban and dabigatran in patients with non-valvular atrial fibrillation: a meta-analysis.
    J Thromb Thrombolysis. 2019 Nov 5. pii: 10.1007/s11239-019-01986.
    PubMed     Abstract available


  17. LIU XH, Gao XF, Chen CF, Chen B, et al
    Thromboembolism and bleeding risk in atrial fibrillation ablation with uninterrupted anticoagulation between new oral anticoagulants and vitamin K antagonists: insights from an updated meta-analysis.
    J Thromb Thrombolysis. 2019 Nov 4. pii: 10.1007/s11239-019-01989.
    PubMed     Abstract available


  18. AMROZE A, Mazor K, Crawford S, O'Day K, et al
    Survey of confidence in use of stroke and bleeding risk calculators, knowledge of anticoagulants, and comfort with prescription of anticoagulation in challenging scenarios: SUPPORT-AF II study.
    J Thromb Thrombolysis. 2019;48:629-637.
    PubMed     Abstract available


  19. WRIGHT JN, Vazquez SR, Kim K, Jones AE, et al
    Assessing patient preferences for switching from warfarin to direct oral anticoagulants.
    J Thromb Thrombolysis. 2019;48:596-602.
    PubMed     Abstract available


    October 2019
  20. VANNUCCHI V, Moroni F, Grifoni E, Marcucci R, et al
    Management of oral anticoagulation in very old patients with non valvular atrial fibrillation related acute ischemic stroke.
    J Thromb Thrombolysis. 2019 Oct 17. pii: 10.1007/s11239-019-01972.
    PubMed     Abstract available


  21. DI GENNARO L, Lancellotti S, De Cristofaro R, De Candia E, et al
    Carbamazepine interaction with direct oral anticoagulants: help from the laboratory for the personalized management of oral anticoagulant therapy.
    J Thromb Thrombolysis. 2019;48:528-531.
    PubMed     Abstract available


    September 2019
  22. GULILAT M, Keller D, Linton B, Pananos AD, et al
    Drug interactions and pharmacogenetic factors contribute to variation in apixaban concentration in atrial fibrillation patients in routine care.
    J Thromb Thrombolysis. 2019 Sep 28. pii: 10.1007/s11239-019-01962.
    PubMed     Abstract available


    August 2019
  23. WOJSZEL ZB, Kasiukiewicz A
    Determinants of anticoagulant therapy in atrial fibrillation at discharge from a geriatric ward: cross sectional study.
    J Thromb Thrombolysis. 2019 Aug 30. pii: 10.1007/s11239-019-01937.
    PubMed     Abstract available


  24. IKEDA T, Ogawa S, Kitazono T, Nakagawara J, et al
    Outcomes associated with under-dosing of rivaroxaban for management of non-valvular atrial fibrillation in real-world Japanese clinical settings.
    J Thromb Thrombolysis. 2019 Aug 20. pii: 10.1007/s11239-019-01934.
    PubMed     Abstract available


  25. RUSSO V, Attena E, Di Maio M, Mazzone C, et al
    Clinical profile of direct oral anticoagulants versus vitamin K anticoagulants in octogenarians with atrial fibrillation: a multicentre propensity score matched real-world cohort study.
    J Thromb Thrombolysis. 2019 Aug 5. pii: 10.1007/s11239-019-01923.
    PubMed     Abstract available


    July 2019
  26. SAMOS M, Bolek T, Skornova I, Benko J, et al
    Apixaban: a novel agent to treat heparin induced thrombocytopenia and to prevent embolism in patient with atrial fibrillation after multiple valve replacement?
    J Thromb Thrombolysis. 2019 Jul 1. pii: 10.1007/s11239-019-01910.
    PubMed     Abstract available


    June 2019
  27. MIAO B, Alberts MJ, Bunz TJ, Coleman CI, et al
    Safety and effectiveness of oral factor Xa inhibitors versus warfarin in nonvalvular atrial fibrillation patients at high-risk for falls.
    J Thromb Thrombolysis. 2019 Jun 21. pii: 10.1007/s11239-019-01898.
    PubMed     Abstract available


  28. OSMAN M, Kheiri B, Munir MB, Moreland JA, et al
    The fading role of triple therapy in patients with atrial fibrillation and acute coronary syndrome: a Bayesian network meta-analysis.
    J Thromb Thrombolysis. 2019 Jun 7. pii: 10.1007/s11239-019-01896.
    PubMed    


  29. KE HH, He Y, Lv XW, Zhang EH, et al
    Efficacy and safety of rivaroxaban on the resolution of left atrial/left atrial appendage thrombus in nonvalvular atrial fibrillation patients.
    J Thromb Thrombolysis. 2019 Jun 5. pii: 10.1007/s11239-019-01876.
    PubMed     Abstract available


    May 2019
  30. GRUCA MM, Li Y, Kong X, DeCamillo D, et al
    Creatinine monitoring patterns in the setting of direct oral anticoagulant therapy for non-valvular atrial fibrillation.
    J Thromb Thrombolysis. 2019 May 20. pii: 10.1007/s11239-019-01883.
    PubMed     Abstract available


  31. KHEIRI B, Osman M, Bakhit A, Radaideh Q, et al
    Dual versus triple therapy for patients with atrial fibrillation and acute coronary syndrome: a meta-analysis and trial sequential analysis of randomized controlled trials.
    J Thromb Thrombolysis. 2019 May 3. pii: 10.1007/s11239-019-01874.
    PubMed    


    April 2019
  32. GUIMARAES PO, Lopes RD, Alexander JH, Thomas L, et al
    International normalized ratio control and subsequent clinical outcomes in patients with atrial fibrillation using warfarin.
    J Thromb Thrombolysis. 2019 Apr 10. pii: 10.1007/s11239-019-01858.
    PubMed     Abstract available


  33. SCHOAPS RS, Quintili A, Bonavia A, Carr ZJ, et al
    Stroke prophylaxis in critically-ill patients with new-onset atrial fibrillation.
    J Thromb Thrombolysis. 2019 Apr 8. pii: 10.1007/s11239-019-01854.
    PubMed     Abstract available


  34. OKISHIGE K, Yamauchi Y, Hanaki Y, Inoue K, et al
    Clinical experience of idarucizumab use in cases of cardiac tamponade under uninterrupted anticoagulation of dabigatran during catheter ablation of atrial fibrillation.
    J Thromb Thrombolysis. 2019 Apr 6. pii: 10.1007/s11239-019-01835.
    PubMed     Abstract available


  35. WASHAM JB, Hohnloser SH, Lopes RD, Wojdyla DM, et al
    Interacting medication use and the treatment effects of apixaban versus warfarin: results from the ARISTOTLE Trial.
    J Thromb Thrombolysis. 2019;47:345-352.
    PubMed     Abstract available


    March 2019
  36. AMIN A, Keshishian A, Dina O, Dhamane A, et al
    Comparative clinical outcomes between direct oral anticoagulants and warfarin among elderly patients with non-valvular atrial fibrillation in the CMS medicare population.
    J Thromb Thrombolysis. 2019 Mar 28. pii: 10.1007/s11239-019-01838.
    PubMed     Abstract available


  37. CROSTA F, Desideri G, Marini C
    Leukoaraiosis is an independent predictor of intracranial hemorrhage in patients with atrial fibrillation.
    J Thromb Thrombolysis. 2019 Mar 14. pii: 10.1007/s11239-019-01839.
    PubMed     Abstract available


  38. KARTAS A, Samaras A, Vasdeki D, Dividis G, et al
    Hospitalization affects the anticoagulation patterns of patients with atrial fibrillation.
    J Thromb Thrombolysis. 2019 Mar 4. pii: 10.1007/s11239-019-01832.
    PubMed     Abstract available


    February 2019
  39. STANKOVIC P, Georgiew R, Frommelt C, Hammel S, et al
    Shorter hospital stays in epistaxis patients with atrial fibrillation when taking rivaroxaban or apixaban versus phenprocoumon.
    J Thromb Thrombolysis. 2019 Feb 7. pii: 10.1007/s11239-019-01824.
    PubMed     Abstract available


  40. BJORCK F, Kadhim H, Sjalander A
    Predictors for INR-control in a well-managed warfarin treatment setting.
    J Thromb Thrombolysis. 2019;47:227-232.
    PubMed     Abstract available


    January 2019
  41. HIRSH RACCAH B, Rottenstreich A, Zacks N, Matok I, et al
    Appropriateness of direct oral anticoagulant dosing and its relation to drug levels in atrial fibrillation patients.
    J Thromb Thrombolysis. 2019 Jan 28. pii: 10.1007/s11239-019-01815.
    PubMed     Abstract available


    December 2018
  42. WANG CL, Wu VC, Lee CH, Kuo CF, et al
    Effectiveness and safety of non-vitamin-K antagonist oral anticoagulants versus warfarin in atrial fibrillation patients with thrombocytopenia.
    J Thromb Thrombolysis. 2018 Dec 18. pii: 10.1007/s11239-018-1792.
    PubMed     Abstract available


    November 2018
  43. MASOTTI L, Grifoni E, Dei A, Vannucchi V, et al
    Direct oral anticoagulants in the early phase of non valvular atrial fibrillation-related acute ischemic stroke: focus on real life studies.
    J Thromb Thrombolysis. 2018 Nov 23. pii: 10.1007/s11239-018-1775.
    PubMed     Abstract available


  44. HOWE Z, Naville-Cook C, Cole D
    Bleeding rates of Veterans taking apixaban or rivaroxaban for atrial fibrillation or venous thromboembolism.
    J Thromb Thrombolysis. 2018 Nov 17. pii: 10.1007/s11239-018-1770.
    PubMed     Abstract available


  45. CHOPARD R, Piazza G, Hurwitz S, Fanikos J, et al
    Fatal warfarin-associated intracranial hemorrhage in atrial fibrillation inpatients.
    J Thromb Thrombolysis. 2018 Nov 17. pii: 10.1007/s11239-018-1767.
    PubMed     Abstract available


    October 2018
  46. BOLEK T, Samos M, Skornova I, Stanciakova L, et al
    Does proton pump inhibition change the on-treatment anti-Xa activity in xabans-treated patients with atrial fibrillation? A pilot study.
    J Thromb Thrombolysis. 2018 Oct 4. pii: 10.1007/s11239-018-1748.
    PubMed     Abstract available


  47. SOKOL J, Nehaj F, Ivankova J, Mokan M, et al
    First evidence: rivaroxaban and apixaban reduce thrombin-dependent platelet aggregation.
    J Thromb Thrombolysis. 2018;46:393-398.
    PubMed     Abstract available


  48. CAPPELLARI M, Turcato G, Forlivesi S, Micheletti N, et al
    Introduction of direct oral anticoagulant within 7 days of stroke onset: a nomogram to predict the probability of 3-month modified Rankin Scale score > 2.
    J Thromb Thrombolysis. 2018;46:292-298.
    PubMed     Abstract available


    September 2018
  49. HIRSH RACCAH B, Rottenstreich A, Zacks N, Muszkat M, et al
    Drug interaction as a predictor of direct oral anticoagulant drug levels in atrial fibrillation patients.
    J Thromb Thrombolysis. 2018 Sep 8. pii: 10.1007/s11239-018-1738.
    PubMed     Abstract available


    August 2018
  50. MAZUR P, Myc J, Natorska J, Plens K, et al
    Impaired fibrinolysis in degenerative mitral and aortic valve stenosis.
    J Thromb Thrombolysis. 2018;46:193-202.
    PubMed     Abstract available


  51. POLNAK JF, Delate T, Clark NP
    The influence of fibrate initiation on INR and warfarin dose in patients receiving chronic warfarin therapy.
    J Thromb Thrombolysis. 2018;46:264-270.
    PubMed     Abstract available


  52. SHIROSHITA A, Nakashima K, Tanaka Y, Tateishi A, et al
    Successful treatment with idarucizumab for diffuse alveolar hemorrhage induced by dabigatran etexilate: a case report.
    J Thromb Thrombolysis. 2018;46:271-273.
    PubMed     Abstract available


    July 2018
  53. JACKSON LR 2ND, Kim S, Shrader P, Blanco R, et al
    Early therapeutic persistence on dabigatran versus warfarin therapy in patients with atrial fibrillation: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry.
    J Thromb Thrombolysis. 2018 Jul 26. pii: 10.1007/s11239-018-1715.
    PubMed     Abstract available


  54. AGIRBASLI M
    Quality of direct oral anticoagulant therapy in elderly patients with non-valvular atrial fibrillation.
    J Thromb Thrombolysis. 2018 Jul 25. pii: 10.1007/s11239-018-1717.
    PubMed    


    June 2018
  55. CHI G, Yee MK, Kalayci A, Kerneis M, et al
    Total bleeding with rivaroxaban versus warfarin in patients with atrial fibrillation receiving antiplatelet therapy after percutaneous coronary intervention.
    J Thromb Thrombolysis. 2018 Jun 26. pii: 10.1007/s11239-018-1703.
    PubMed     Abstract available


  56. KHEIRI B, Haykal T, Abdalla A, Osman M, et al
    Non-vitamin K antagonist oral anticoagulants in cardioversion of atrial fibrillation: a network meta-analysis.
    J Thromb Thrombolysis. 2018 Jun 15. pii: 10.1007/s11239-018-1694.
    PubMed    


  57. HUGHEY AB, Gu X, Haymart B, Kline-Rogers E, et al
    Warfarin for prevention of thromboembolism in atrial fibrillation: comparison of patient characteristics and outcomes of the "Real-World" Michigan Anticoagulation Quality Improvement Initiative (MAQI(2)) registry to the RE-LY, ROCKET-AF, and ARISTOTLE
    J Thromb Thrombolysis. 2018 Jun 14. pii: 10.1007/s11239-018-1698.
    PubMed     Abstract available


  58. MONAGLE SR, Hirsh J, Bhagirath VC, Ginsberg JS, et al
    Impact of cost on use of non-vitamin K antagonists in atrial fibrillation patients in Ontario, Canada.
    J Thromb Thrombolysis. 2018 Jun 5. pii: 10.1007/s11239-018-1692.
    PubMed     Abstract available


    May 2018
  59. ROSSI AP, Facchinetti R, Ferrari E, Nori N, et al
    Predictors of self-reported adherence to direct oral anticoagulation in a population of elderly men and women with non-valvular atrial fibrillation.
    J Thromb Thrombolysis. 2018 May 14. pii: 10.1007/s11239-018-1679.
    PubMed     Abstract available


  60. HOYER C, Filipov A, Neumaier-Probst E, Szabo K, et al
    Impact of pre-admission treatment with non-vitamin K oral anticoagulants on stroke severity in patients with acute ischemic stroke.
    J Thromb Thrombolysis. 2018;45:529-535.
    PubMed     Abstract available


  61. FASULLO S, Davi S, Cosenza G, Di Franco F, et al
    Acute agranulocytosis after oral administration of dabigatran: a rare case report and a short review of literature.
    J Thromb Thrombolysis. 2018;45:588-592.
    PubMed     Abstract available


    April 2018
  62. GRANT SJ, Kothari S, Gimotty PA, Gooneratne NS, et al
    Quality of direct oral anticoagulant prescribing in elderly patients with non-valvular atrial fibrillation: results from a large urban health system.
    J Thromb Thrombolysis. 2018 Apr 2. pii: 10.1007/s11239-018-1651.
    PubMed     Abstract available


    February 2018
  63. BRUNETTI ND, Tarantino N, De Gennaro L, Correale M, et al
    Direct oral anti-coagulants compared to vitamin-K antagonists in cardioversion of atrial fibrillation: an updated meta-analysis.
    J Thromb Thrombolysis. 2018 Feb 5. pii: 10.1007/s11239-018-1622.
    PubMed     Abstract available


    January 2018
  64. XIANG E, Ahuja T, Raco V, Cirrone F, et al
    Anticoagulation prescribing patterns in patients with cancer.
    J Thromb Thrombolysis. 2018;45:89-98.
    PubMed     Abstract available


    December 2017
  65. RUSSO V, Rago A, Papa AA, D'Onofrio A, et al
    Efficacy and safety of dabigatran in patients with atrial fibrillation scheduled for transoesophageal echocardiogram-guided direct electrical current cardioversion: a prospective propensity score-matched cohort study.
    J Thromb Thrombolysis. 2017 Dec 19. pii: 10.1007/s11239-017-1599.
    PubMed     Abstract available


  66. SHIN H, Cho MC, Kim RB, Kim CH, et al
    Laboratory measurement of apixaban using anti-factor Xa assays in acute ischemic stroke patients with non-valvular atrial fibrillation.
    J Thromb Thrombolysis. 2017 Dec 2. pii: 10.1007/s11239-017-1590.
    PubMed     Abstract available


    July 2017
  67. PIPILIS A, Makrygiannis S, Anagnostou G, Kaliampakos S, et al
    Dabigatran plasma levels, aPTT and thromboelastography in patients with AF: implications for allowing early non-elective surgical procedures.
    J Thromb Thrombolysis. 2017;44:9-13.
    PubMed     Abstract available


    June 2017
  68. HELMERT S, Marten S, Mizera H, Reitter A, et al
    Effectiveness and safety of apixaban therapy in daily-care patients with atrial fibrillation: results from the Dresden NOAC Registry.
    J Thromb Thrombolysis. 2017 Jun 22. doi: 10.1007/s11239-017-1519.
    PubMed     Abstract available


    March 2017
  69. STEPPICH B, Dobler F, Brendel LC, Hessling G, et al
    Effect of the FXa inhibitors Rivaroxaban and Apixaban on platelet activation in patients with atrial fibrillation.
    J Thromb Thrombolysis. 2017 Mar 18. doi: 10.1007/s11239-017-1495.
    PubMed     Abstract available


    February 2017
  70. MARSICO F, Cecere M, Parente A, Paolillo S, et al
    Effects of novel oral anticoagulants on left atrial and left atrial appendage thrombi: an appraisal.
    J Thromb Thrombolysis. 2017;43:139-148.
    PubMed     Abstract available


    August 2016
  71. ROSWELL RO, Greet B, Shah S, Bernard S, et al
    Intravenous heparin dosing strategy in hospitalized patients with atrial dysrhythmias.
    J Thromb Thrombolysis. 2016;42:179-85.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Arrhythmias is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: